Coya Therapeutics Hosts Webinar on ALS Drug Development and Clinical Progress

Reuters

Feb 10

<a href="https://laohu8.com/S/COYA">Coya Therapeutics</a> Hosts Webinar on ALS Drug Development and Clinical Progress

Coya Therapeutics Inc., a clinical-stage biotechnology company focused on enhancing T-cell (Treg) function for neurodegenerative disorders, will host a live webinar titled "Inside the Evolving ALS Landscape: Biology, Innovation, and Clinical Progress" on February 17, 2026, at 3:00 p.m. ET / 12:00 p.m. PT. The event will feature leading medical experts, including Dr. Stanley Appel and Dr. James Berry, who will discuss recent breakthroughs, challenges, and drug development advances in ALS, with a focus on Coya's novel immunotherapy approach and the ALSTARS Phase 2 clinical trial. Pre-registration for the webinar is now open HERE. A recording of the event will be posted to the Coya Therapeutics website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260210471934) on February 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610628530"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610628530\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610628530?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610628530","market":"fut","top_or_hot":-1,"title":"Coya Therapeutics Hosts Webinar on ALS Drug Development and Clinical Progress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/COYA\">Coya Therapeutics</a> Hosts Webinar on ALS Drug Development and Clinical Progress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Coya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a clinical-stage biotechnology company focused on enhancing T-cell (Treg) function for neurodegenerative disorders, will host a live webinar titled \"Inside the Evolving ALS Landscape: Biology, Innovation, and Clinical Progress\" on February 17, 2026, at 3:00 p.m. ET / 12:00 p.m. PT. The event will feature leading medical experts, including Dr. Stanley Appel and Dr. James Berry, who will discuss recent breakthroughs, challenges, and drug development advances in ALS, with a focus on Coya's novel immunotherapy approach and the ALSTARS Phase 2 clinical trial. Pre-registration for the webinar is now open HERE. A recording of the event will be posted to the Coya Therapeutics website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260210471934) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coya Therapeutics Hosts Webinar on ALS Drug Development and Clinical Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoya Therapeutics Hosts Webinar on ALS Drug Development and Clinical Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-10 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/COYA\">Coya Therapeutics</a> Hosts Webinar on ALS Drug Development and Clinical Progress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Coya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a clinical-stage biotechnology company focused on enhancing T-cell (Treg) function for neurodegenerative disorders, will host a live webinar titled \"Inside the Evolving ALS Landscape: Biology, Innovation, and Clinical Progress\" on February 17, 2026, at 3:00 p.m. ET / 12:00 p.m. PT. The event will feature leading medical experts, including Dr. Stanley Appel and Dr. James Berry, who will discuss recent breakthroughs, challenges, and drug development advances in ALS, with a focus on Coya's novel immunotherapy approach and the ALSTARS Phase 2 clinical trial. Pre-registration for the webinar is now open HERE. A recording of the event will be posted to the Coya Therapeutics website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260210471934) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COYA","symbol_name":"COYA THERAPEUTICS INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL6SNSkf:1","article_id":"2610628530","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610628530","pubTimestamp":1770728527,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Coya Therapeutics Inc., a clinical-stage biotechnology company focused on enhancing T-cell  function for neurodegenerative disorders, will host a live webinar titled \"Inside the Evolving ALS Landscape: Biology, Innovation, and Clinical Progress\" on February 17, 2026, at 3:00 p.m. ET / 12:00 p.m. PT. The event will feature leading medical experts, including Dr. Stanley Appel and Dr. James Berry, who will discuss recent breakthroughs, challenges, and drug development advances in ALS, with a focus on Coya's novel immunotherapy approach and the ALSTARS Phase 2 clinical trial. Pre-registration for the webinar is now open HERE. A recording of the event will be posted to the Coya Therapeutics website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ad","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COYA":"COYA THERAPEUTICS INC","BK4139":"生物科技"},"translate_title":"Coya Therapeutics举办ALS药物开发和临床进展网络研讨会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COYA":0.9},"content_text":"Coya Therapeutics Hosts Webinar on ALS Drug Development and Clinical Progress\n    \n\n        Coya Therapeutics Inc., a clinical-stage biotechnology company focused on enhancing T-cell (Treg) function for neurodegenerative disorders, will host a live webinar titled \"Inside the Evolving ALS Landscape: Biology, Innovation, and Clinical Progress\" on February 17, 2026, at 3:00 p.m. ET / 12:00 p.m. PT. The event will feature leading medical experts, including Dr. Stanley Appel and Dr. James Berry, who will discuss recent breakthroughs, challenges, and drug development advances in ALS, with a focus on Coya's novel immunotherapy approach and the ALSTARS Phase 2 clinical trial. Pre-registration for the webinar is now open HERE. A recording of the event will be posted to the Coya Therapeutics website.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260210471934) on February 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}